北京德恒律师事务所 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于凯莱英医药集团（天津）股份有限公司 2025 年 A 股限制性股票激励计划 回购价格调整及回购注销部分限制性股票事项的法律意见 | 一、关于本次回购注销及价格调整的批准和授权 | 3 | | --- | --- | | 二、关于本次回购注销的原因、价格调整、数量及资金来源 | 5 | | 三、结论意见 | 6 | 关于 凯莱英医药集团（天津）股份有限公司 2025 年 A 股限制性股票激励计划 回购价格调整及回购注销部分限制性股票事项的 1 北京德恒律师事务所 关于凯莱英医药集团（天津）股份有限公司 2025 年 A 股限制性股票激励计划 回购价格调整及回购注销部分限制性股票事项的法律意见 北京德恒律师事务所 关于凯莱英医药集团（天津）股份有限公司 2025 年 A 股限制性股票激励计划回购价格调整及 回购注销部分限制性股票事项的法律意见 德恒 01F20250024-04 号 致：凯莱英医药集团（天津）股份有限公司 ...

凯莱英医药集团（天津）股份有限公司 董事及高级管理人员薪酬管理制度 （2025 年 12 月修订） 凯莱英医药集团（天津）股份有限公司 董事及高级管理人员薪酬管理制度 第一章 总则 第二条 本制度所称董事，是指本制度执行期间公司董事会的全部在职 成员，包括执行董事及非执行董事（含独立非执行董事）。 本制度所称高级管理人员，是指首席执行官（CEO）、联席首席执行官（Co- CEO）、首席科学官（CSO）、首席运营官（COO）、首席财务官（CFO）、首席技 术官（CTO）、首席商务官（CBO）、以及由董事会聘任的执行副总裁、高级副总 裁、副总裁、董事会秘书。 第三条 董事、高级管理人员薪酬与市场发展相适应，与公司经营业绩、个 人业绩相匹配，与公司可持续发展相协调，保障公司的长期稳定发展，董事、高 级管理人员薪酬与公司效益及工作目标紧密结合，同时与市场价值规律相符。公 司薪酬制度遵循以下原则： （一）竞争力原则：公司提供的薪酬与市场同等职位收入水平相比有竞争力； （二）按岗位确定薪酬原则：公司内部各岗位薪酬体现各岗位对公司的价值， 体现"责、权、利"的统一； （三）与绩效挂钩的原则； （四）短期与中长期激励相结合的 ...

凯莱英医药集团（天津）股份有限公司 内部控制制度 （2025 年 12 月修订） 1 凯莱英医药集团（天津）股份有限公司 内部控制制度 第一章 总则 第一条 为加强凯莱英医药集团（天津）股份有限公司（以下简称"公司"） 的内部控制，促进公司规范运作和健康发展，保护股东合法权益，根据《中华 人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规 则》（以下简称《上市规则》）、《深圳证券交易所上市公司自律监管指引第1 号—主板上市公司规范运作》等法律、法规、规范性文件和《凯莱英医药集团 （天津）股份有限公司章程》（以下简称"《公司章程》"）的规定，结合公 司实际，特修订完善本制度。 （四）确保公司信息披露的真实、准确、完整和公平。 第三条 公司董事会负责公司内部控制制度的制定和有效执行，审计委员会 负责审查企业内部控制，监督内部控制的有效实施和内部控制自我评价情况， 协调内部控制审计及其他相关事宜等。 第二章 内部控制的内容 第四条 公司的内部控制充分考虑到以下要素： （一）内部环境：内部环境是企业实施内部控制的基础，一般包括治理结 构、机构设置及权责分配、内部审计、人力资源政策、企业文化等； 2 ...

2025年1至6月份，凯莱英的营业收入构成为：医药行业占比99.9%，其他业务占比0.1%。 截至发稿，凯莱英市值为342亿元。 每经AI快讯，凯莱英（SZ 002821，收盘价：94.79元）12月19日晚间发布公告称，公司第五届第六次董 事会会议于2025年12月19日以通讯方式召开。会议审议了《关于修订 <凯莱英医药集团 天津="天津" 股 份有限公司董事及高级管理人员薪酬管理制度="股份有限公司董事及高级管理人员薪酬管理制度"> 的 议案》等文件。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 曾健辉） ...

凯莱英医药集团（天津）股份有限公司 一、董事会薪酬与考核委员会对调整 2025 年 A 股限制性股票激励计划相关 事项的核查意见 鉴于公司 2024 年年度权益分派已实施完成，根据《上市公司股权激励管理 办法》及公司《2025 年 A 股限制性股票激励计划》的相关规定，公司应对首次 授予部分回购价格进行调整。同意公司对 2025 年 A 股限制性股票激励计划首次 授予部分回购价格进行调整，回购价格由 37.52 元/股调整为 36.42 元/股。 二、董事会薪酬与考核委员会对回购注销 2025 年 A 股限制性股票激励计划 部分限制性股票的核查意见 鉴于 2025 年 A 股限制性股票激励计划首次授予激励对象 7 人及预留授予激 励对象 1 人已从公司离职，前述人员已获授但尚未解除限售的限制性股票 33,000 股应由公司回购注销。本次回购注销部分限制性股票事项符合《上市公司股权激 励管理办法》及公司《2025 年 A 股限制性股票激励计划》的相关规定。同意本 次回购注销 33,000 股限制性股票事项。 董事会薪酬与考核委员会关于公司2025年A股限制性股票激励计划 相关事项的核查意见 凯莱英医药集团（天津 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-066 凯莱英医药集团（天津）股份有限公司 第五届董事会第六次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）第五届董事会 第六次会议通知于 2025 年 12 月 13 日以电子邮件及书面形式发送给各位董事及 高级管理人员，会议于 2025 年 12 月 19 日以通讯方式召开。公司应到董事 9 名， 实到董事 9 名。公司部分高级管理人员列席了本次会议。本次会议由公司董事长 HAO HONG 先生召集和主持，会议的召集和召开符合《公司法》及相关法律、 法规以及《公司章程》的有关规定。 二、董事会议案审议情况 会议采用通讯方式召开，经全体与会董事审议并表决，通过了如下决议： 1、审议通过了《关于调整2025年A股限制性股票激励计划相关事项的议案》 根据公司《2025 年 A 股限制性股票激励计划》相关规定："激励对象获授 的限制性股票完成股份登记后，若公司发生资本公积转增股本、派送股票红利、 股份拆细、配 ...

凯莱英公告，拟回购注销33000股限制性股票。公司2025年A股限制性股票激励计划首次授予激励对象7 人及预留授予激励对象1人已从公司离职，根据公司《2025年A股限制性股票激励计划》相关规定，激 励对象因辞职、公司裁员而离职，激励对象根据本计划已获授但尚未解除限售的限制性股票不得解除限 售，由公司以授予价格回购注销。 ...

Market Overview - US inflation slowdown supports interest rate cut expectations, while the Bank of Japan raised rates by 25 basis points, leading to a rise in Hong Kong's three major indices. The Hang Seng Index increased by 0.75% to 25,690.53 points with a total turnover of HKD 221.186 billion [1] - The Hang Seng Index experienced a cumulative decline of 1.1% for the week, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.96% and 2.82%, respectively [1] Blue Chip Performance - Shenzhou International (02313) led the decline among blue chips, falling by 3.18% to HKD 60.95, with a turnover of HKD 490 million, negatively impacting the Hang Seng Index by 2.67 points. Despite exceeding market expectations in revenue and profit, the company's net profit dropped by 32% year-on-year due to declining profit margins and pressures on direct sales [2] - Other notable blue chip performances included WuXi Biologics (02269) rising by 4.4% and Li Auto-W (02015) increasing by 3.81% [2] Sector Highlights - Large tech stocks mostly rose, with Tencent, Kuaishou, and Meituan each gaining over 1%. The L3-level autonomous driving sector saw significant activity, while pharmaceutical stocks rebounded sharply [3] - The L3-level autonomous driving concept stocks surged, with Youjia Innovation (02431) up by 31.22% and Xiaopeng Motors-W (09868) rising by 7.65%. The Ministry of Industry and Information Technology's approval of L3-level autonomous driving vehicles is expected to accelerate the industry's value reconstruction [3] - Pharmaceutical stocks also saw a notable rebound, with Kelaiying (06821) increasing by 10.42% and WuXi Biologics (02269) up by 4.4%. The geopolitical concerns regarding China's CXO industry are expected to stabilize, supporting innovation in the sector [4] Lithium Industry - Lithium stocks experienced a rally, with Ganfeng Lithium (01772) rising by 1.87% and Tianqi Lithium (09696) increasing by 1.72%. The price of lithium carbonate futures broke through the 110,000 yuan mark [4][5] Robotics Sector - The robotics sector was active, with Hong Kong Robot (00370) rising by 10.29%. Recent collaborations in the humanoid robot space are expected to drive market growth, with projections indicating a potential market size of USD 5 trillion by 2050 [6] Notable New Listings - New listings showed a stark contrast, with Zhihui Mining (02546) surging by 90.69% while Xidi Intelligent Driving (03881) fell by 13.69% on their debut [7] Company-Specific Developments - CIMC Group (02039) saw a strong performance, rising by 15.47% after announcing a buyback plan for H-shares worth up to HKD 300 million [8] - Changfei Optical Fiber (06869) climbed by 12.01%, driven by signs of recovery in the traditional optical fiber market and growth in the overseas special optical fiber market [9] - China Duty Free Group (01880) rose by 6.88% following the launch of the Hainan Free Trade Port, with expectations of increased offshore duty-free sales [10] - China Tobacco Hong Kong (06055) increased by 6.68% amid new regulations aimed at strengthening electronic cigarette oversight, with positive outlooks for the tobacco sector [11]

Market Overview - US inflation slowdown supports interest rate cut expectations, while the Bank of Japan raised rates by 25 basis points, leading to a rise in Hong Kong's three major indices. The Hang Seng Index increased by 0.75% to 25,690.53 points, with a total turnover of HKD 221.186 billion. The Hang Seng China Enterprises Index rose by 0.68%, and the Hang Seng Tech Index increased by 1.12% [1] Blue Chip Performance - Shenzhou International (02313) led the decline among blue chips, falling by 3.18% to HKD 60.95, with a turnover of HKD 490 million. Despite exceeding revenue and profit expectations, its net profit dropped by 32% year-on-year due to declining profit margins and ongoing pressures in direct sales [2] - Other blue chips included WuXi Biologics (02269), which rose by 4.4%, and Li Auto-W (02015), which increased by 3.81% [2] Sector Highlights - Large tech stocks mostly rose, with Tencent, Kuaishou, and Meituan gaining over 1%. The L3-level autonomous driving sector saw significant activity, with stocks like Xiaopeng Motors rising over 7% [3] - The pharmaceutical sector rebounded significantly, with companies like Kelun Pharmaceutical (06821) rising by 10.42% and WuXi Biologics (02269) increasing by 4.4% [4] - Lithium stocks also saw gains, with Ganfeng Lithium (01772) up by 1.87% and Tianqi Lithium (09696) rising by 1.72% [4] New Listings - New stocks showed a clear divergence, with Zhihui Mining (02546) soaring by 90.69% to HKD 8.6, while Xidi Intelligent Driving (03881) fell by 13.69% to HKD 227 [7] Company Developments - CIMC Group (02039) saw a strong performance, rising by 15.47% to HKD 8.88 after announcing a buyback plan for H-shares [8] - Changfei Optical Fiber (06869) surged by 12.01% to HKD 51.75, driven by signs of recovery in the optical fiber market [9] - China Duty Free Group (01880) saw its A and H shares rise by 6.88% to HKD 70.7, with expectations of increased sales due to optimized offshore duty-free shopping policies [10] - China Tobacco Hong Kong (06055) rose by 6.68% to HKD 34.48, supported by new regulations aimed at strengthening electronic cigarette oversight [11]

Group 1: Policy and Regulatory Developments - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025)" and the "Commercial Health Insurance Innovative Drug Catalog (2025)", effective from January 1, 2026, nationwide [1] - The medical insurance catalog adds 114 new drugs, including 50 innovative first-class drugs, with an overall success rate of 88%, a 12 percentage point increase from 2024 [1] - The first version of the commercial health insurance innovative drug catalog includes 19 drugs, marking a significant breakthrough in the "medical insurance + commercial insurance" multi-layered medical security system [1] Group 2: Market Trends and Investment Opportunities - The Chinese innovative drug sector is experiencing active out-licensing (BD) transactions, with a total transaction amount exceeding $92 billion and 103 deals completed in the first three quarters of 2025, indicating strong international recognition of Chinese R&D achievements [2] - The innovative drug R&D is entering a harvest period, with pipeline values gradually being realized, supported by overseas payment capabilities and a shift towards hard-core technology-driven growth [2] - Emerging technologies such as small nucleic acids, in vivo CAR-T, and AI drug development platforms are expected to see a clinical value explosion, while the CXO industry remains robust, benefiting from new tracks like ADC, peptides, and CGT [2] Group 3: ETF Performance and Market Sentiment - As of December 18, 2025, the Hong Kong innovative drug ETF (513120) has seen a strong increase of 10.56% over the past six months, with significant contributions from major stocks like WuXi Biologics and 3SBio [3] - The latest scale of the Hong Kong innovative drug ETF reached 24.322 billion yuan, making it the largest in the Hong Kong market for pharmaceutical ETFs, with a net inflow of 327 million yuan over the past five trading days [3] - The innovative drug ETF (515120) also experienced a rise, with major stocks like Zai Lab and WuXi AppTec contributing to the gains, indicating a positive market sentiment towards innovative drug investments [4]